FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileArgenica Therapeutics Ltd
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
AGN.AX
Argenica Therapeutics Ltd Stock AnalysisComprehensive stock analysis for Argenica Therapeutics Ltd (AGN.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAGN.AX
AGN.AX
Argenica Therapeutics Ltd
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
AGN.AX
  1. Home
  2. Stocks
  3. Argenica Therapeutics Ltd

Argenica Therapeutics Ltd

🇦🇺AGN.AX•ASX

Argenica Therapeutics Ltd

🇦🇺AGN.AX•ASX

Your view on AGN.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Argenica Therapeutics Ltd

Industry
Biotechnology
Sector
Healthcare
CEO
Liz Dallimore
Headquarters
117 Broadway, Nedlands, WA, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Liz Dallimore
Headquarters
117 Broadway, Nedlands, WA, AU
Description

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury.

The company was incorporated in 2019 and is based in Nedlands, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Argenica Therapeutics Ltd. Starting points for Argenica Therapeutics Ltd: EPS -AUD 0.01, beta 0.71 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Argenica Therapeutics Ltd. Argenica Therapeutics Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Argenica Therapeutics Ltd. Trailing twelve-month EPS for Argenica Therapeutics Ltd stands at -AUD 0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
More →

Earnings per share estimates

Per shareThis yearYear to Jun 2027Next yearYear to Jun 2028
Average estimate−AUD 0.07AUD 0.21
Lowest estimate−AUD 0.07AUD 0.21
Highest estimate−AUD 0.07AUD 0.21
Number of analysts11
A year ago−AUD 0.011—
Growth vs a year ago——

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 28.10MAUD 6.70M
Lowest estimateAUD 28.10MAUD 6.70M
Highest estimateAUD 28.10MAUD 6.70M
Number of analysts11
A year agoAUD 0.00—
Growth vs a year ago——

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Argenica Therapeutics Ltd. Argenica Therapeutics Ltd has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold AGN.AX20 companies
Compare AGN.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
ADO.AXAnteoTech LimitedBasic MaterialsChemicals - Specialty—
BDX.AXBCAL Diagnostics LimitedHealthcareMedical - Diagnostics & Research—
EMD.AXEmyria LimitedHealthcareMedical - Healthcare Information Services—
EYE.AXNova Eye Medical LimitedHealthcareMedical - Devices—
IIQ.AXINOVIQ LtdHealthcareMedical - Diagnostics & Research—
IMC.AXImmuron LimitedHealthcareBiotechnology—
MAP.AXMicroba Life Sciences LimitedHealthcareMedical - Diagnostics & Research—
NOX.AXNoxopharm LimitedHealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PFNDPathfinder Cell Therapy, Inc.HealthcareOTC$66,716
PGENPrecigen, Inc.HealthcareNASDAQ$1.5B
PHARPharming Group N.V.HealthcareNASDAQ$882.4M
PHATPhathom Pharmaceuticals, Inc.HealthcareNASDAQ$430.8M
PHGUFPharming Group N.V.HealthcareOTC$1.1B
PHIOPhio Pharmaceuticals Corp.HealthcareNASDAQ$8.6M
PHMMFPharma Mar, S.A.HealthcareOTC$1.5B
PHRM.CNPharmaTher Holdings Ltd.HealthcareCNQ$9.1M
PHRRFPharmaTher Holdings Ltd.HealthcareOTC$5.3M
PHVSPharvaris N.V.HealthcareNASDAQ$2.2B
PHYOFIXICO plcHealthcareOTC$6.5M
PKTXProtoKinetix, IncorporatedHealthcareOTC$2.7M
Open Comparable Analysis
Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Argenica Therapeutics Ltd.

AGN.AX AnalysisFair
Past
1
Growth
5
Health
5
Profit
1
Value
1